Akebia Therapeutics, Inc. AKBA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
-12.49
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $236.2M | -$5.3M | — | $67.7M | $32.6M |
| 2024 | $160.2M | -$69.4M | — | -$40.7M | -$49.2M |
| 2023 | $194.6M | -$51.9M | — | -$23.4M | -$30.6M |
| 2022 | $292.5M | -$94.2M | — | -$73.3M | $5.2M |
| 2021 | $213.6M | -$282.0M | — | -$253.0M | $74.0M |
| 2020 | $295.3M | -$383.5M | — | -$110.7M | $247.6M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Wolf Myles | director | 2026-06-17 | Grant | 35,700 | — |
| Smith Cynthia | director | 2026-06-17 | Grant | 35,700 | — |
| ROGERS MICHAEL W | director | 2026-06-17 | Grant | 35,700 | — |
| FRIESON RON | director | 2026-06-17 | Grant | 35,700 | — |
| ZUMWALT LEANNE M | director | 2026-06-17 | Grant | 35,700 | — |
| ADAMS ADRIAN | director | 2026-06-17 | Grant | 35,700 | — |
| Butler John P. | CEO and President | 2026-03-04 | Buy | 69,270 | $1.25 |
| Malabre Richard C | SVP, Chief Accounting Officer | 2026-02-02 | Sell | 36,142 | $1.39 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -12.49 (distress)
- Working capital / assets 0.239
- Retained earnings / assets -4.471
- EBIT / assets 0.062
- Equity / liabilities 0.095
Source: SEC EDGAR filings · CIK 0001517022 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.